Guardant Health, Inc., a prominent biotechnology company specializing in sequencing and cell diagnostics services for cancer patients globally, has recently reported changes in the ownership of its common shares and related restricted stock units by key directors and officers. These updates were disclosed in filings dated June 22, 2026.
The company, based in Palo Alto, United States, trades on the Nasdaq stock exchange and was established with its initial public offering on October 4, 2018. As of June 21, 2026, Guardant Health’s close price stood at $128.83, with a 52-week high of $135 recorded on June 14, 2026, and a 52-week low of $40.35 noted on July 31, 2025. The company’s market capitalization is valued at $17.47 billion USD.
In the recent filings, each of the following directors—Tariq Musa, Potters Myrtle S., Roberto Mignone, Steve E. Krognes, Meghan V. Joyce, and Vijaya Gadde—purchased approximately four thousand shares. These transactions were executed at the prevailing market price at the time. Additionally, the directors exercised or vested their restricted stock units, converting them into common equity. The filings provide an updated account of each director’s shareholdings, reflecting the additional shares held post-transaction.
It is important to note that no significant material changes were reported beyond these ordinary ownership adjustments. The company continues to operate within the Health Care sector, specifically under the Health Care Providers & Services industry. Despite a negative price-to-earnings ratio of -38.66, Guardant Health remains a key player in the biotechnology field, offering critical diagnostic services to cancer patients worldwide. For more detailed information, stakeholders and interested parties can visit the company’s website at www.guardanthealth.com .
